Literature DB >> 19965670

Immunization with host-type CD8{alpha}+ dendritic cells reduces experimental acute GVHD in an IL-10-dependent manner.

Tomomi Toubai1, Chelsea Malter, Isao Tawara, Chen Liu, Evelyn Nieves, Kathleen P Lowler, Yaping Sun, Pavan Reddy.   

Abstract

Little is known about the role of active immunization in suppressing undesirable immune responses. Because CD8alpha(+) dendritic cells (DCs) suppress certain immune responses, we tested the hypothesis that immunization of donors with host-derived CD8alpha(+) DCs will reduce host-specific donor T-cell responses. BALB/c T cells from the animals that were immunized with B6 CD8alpha(+) DCs demonstrated, in vitro and in vivo, significantly reduced proliferation and secretion of inflammatory cytokines but showed enhanced secretion of interleukin-10 (IL-10). The responses against third-party and model antigens were preserved demonstrating antigen specificity. The in vivo relevance was further demonstrated by the reduction on graft-versus-host disease (GVHD) in both a major histocompatibility complex-mismatched clinically relevant BALB/c --> B6 model and major histocompatibility complex-matched, minor-mismatched C3H.SW --> B6 model of GVHD. Immunization of the donors that were deficient in IL-10 (IL-10(-/-)) or with CD8alpha(+) DCs from B6 class II (class II(-/-)) failed to reduce T-cell responses, demonstrating (1) a critical role for secretion of IL-10 by donor T cells and (2) a direct contact between the T cells and the CD8alpha(+) DCs. Together, these data may represent a novel strategy for reducing GVHD and suggest a broad counterintuitive role for vaccination strategies in mitigating undesirable immune responses in an antigen-specific manner.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19965670      PMCID: PMC2810989          DOI: 10.1182/blood-2009-06-229708

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  59 in total

1.  CD4 and CD8 expression by dendritic cell subtypes in mouse thymus and spleen.

Authors:  D Vremec; J Pooley; H Hochrein; L Wu; K Shortman
Journal:  J Immunol       Date:  2000-03-15       Impact factor: 5.422

Review 2.  Dendritic cells and the control of immunity.

Authors:  J Banchereau; R M Steinman
Journal:  Nature       Date:  1998-03-19       Impact factor: 49.962

3.  Host immunobiology and vaccine development.

Authors:  G J Nossal
Journal:  Lancet       Date:  1997-11-01       Impact factor: 79.321

4.  DEC-205 as a marker of dendritic cells with regulatory effects on CD8 T cell responses.

Authors:  V Kronin; L Wu; S Gong; M C Nussenzweig; K Shortman
Journal:  Int Immunol       Date:  2000-05       Impact factor: 4.823

5.  Granulocyte-colony stimulating factor mobilizes T helper 2-inducing dendritic cells.

Authors:  M Arpinati; C L Green; S Heimfeld; J E Heuser; C Anasetti
Journal:  Blood       Date:  2000-04-15       Impact factor: 22.113

6.  Treatment of allograft recipients with donor-specific transfusion and anti-CD154 antibody leads to deletion of alloreactive CD8+ T cells and prolonged graft survival in a CTLA4-dependent manner.

Authors:  N N Iwakoshi; J P Mordes; T G Markees; N E Phillips; A A Rossini; D L Greiner
Journal:  J Immunol       Date:  2000-01-01       Impact factor: 5.422

7.  Long-term survival of skin allografts induced by donor splenocytes and anti-CD154 antibody in thymectomized mice requires CD4(+) T cells, interferon-gamma, and CTLA4.

Authors:  T G Markees; N E Phillips; E J Gordon; R J Noelle; L D Shultz; J P Mordes; D L Greiner; A A Rossini
Journal:  J Clin Invest       Date:  1998-06-01       Impact factor: 14.808

8.  Interleukin-11 promotes T cell polarization and prevents acute graft-versus-host disease after allogeneic bone marrow transplantation.

Authors:  G R Hill; K R Cooke; T Teshima; J M Crawford; J C Keith; Y S Brinson; D Bungard; J L Ferrara
Journal:  J Clin Invest       Date:  1998-07-01       Impact factor: 14.808

9.  A CD4+ T-cell subset inhibits antigen-specific T-cell responses and prevents colitis.

Authors:  H Groux; A O'Garra; M Bigler; M Rouleau; S Antonenko; J E de Vries; M G Roncarolo
Journal:  Nature       Date:  1997-10-16       Impact factor: 49.962

10.  CD8(+) but not CD8(-) dendritic cells cross-prime cytotoxic T cells in vivo.

Authors:  J M den Haan; S M Lehar; M J Bevan
Journal:  J Exp Med       Date:  2000-12-18       Impact factor: 14.307

View more
  17 in total

Review 1.  Dendritic cells and regulation of graft-versus-host disease and graft-versus-leukemia activity.

Authors:  Elizabeth O Stenger; Hēth R Turnquist; Markus Y Mapara; Angus W Thomson
Journal:  Blood       Date:  2012-03-07       Impact factor: 22.113

2.  Induction of acute GVHD by sex-mismatched H-Y antigens in the absence of functional radiosensitive host hematopoietic-derived antigen-presenting cells.

Authors:  Tomomi Toubai; Isao Tawara; Yaping Sun; Chen Liu; Evelyn Nieves; Rebecca Evers; Thea Friedman; Robert Korngold; Pavan Reddy
Journal:  Blood       Date:  2011-11-18       Impact factor: 22.113

Review 3.  Immune regulatory cells in umbilical cord blood and their potential roles in transplantation tolerance.

Authors:  Young-June Kim; Hal E Broxmeyer
Journal:  Crit Rev Oncol Hematol       Date:  2010-08-19       Impact factor: 6.312

Review 4.  Immunopathology and biology-based treatment of steroid-refractory graft-versus-host disease.

Authors:  Tomomi Toubai; John Magenau
Journal:  Blood       Date:  2020-07-23       Impact factor: 22.113

5.  Interleukin-6 modulates graft-versus-host responses after experimental allogeneic bone marrow transplantation.

Authors:  Isao Tawara; Motoko Koyama; Chen Liu; Tomomi Toubai; Dafydd Thomas; Rebecca Evers; Peter Chockley; Evelyn Nieves; Yaping Sun; Kathleen P Lowler; Chelsea Malter; Norihiro Nishimoto; Geoffrey R Hill; Pavan Reddy
Journal:  Clin Cancer Res       Date:  2010-11-03       Impact factor: 12.531

6.  Donor- but not host-derived interleukin-10 contributes to the regulation of experimental graft-versus-host disease.

Authors:  Isao Tawara; Yaping Sun; Chen Liu; Tomomi Toubai; Evelyn Nieves; Rebecca Evers; Mariem Alrubaie; Nathan Mathewson; Hiroya Tamaki; Pavan Reddy
Journal:  J Leukoc Biol       Date:  2012-01-18       Impact factor: 4.962

7.  Host basophils are dispensable for induction of donor T helper 2 cell differentiation and severity of experimental graft-versus-host disease.

Authors:  Isao Tawara; Evelyn Nieves; Chen Liu; Rebecca Evers; Tomomi Toubai; Yaping Sun; Mariem Alrubaie; Pavan Reddy
Journal:  Biol Blood Marrow Transplant       Date:  2011-08-25       Impact factor: 5.742

8.  Tumor antigen-pulsed CD8α(+) dendritic cells induce T cell-mediated graft-versus-tumor effect in vitro.

Authors:  Ning Na; Kang Chen; Jian Zhang; Shanyang He; Qiang Fu; Beili Zhu; Kaiyuan Cao; Lin Xu
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2011-12-16

9.  FLT3L and plerixafor combination increases hematopoietic stem cell mobilization and leads to improved transplantation outcome.

Authors:  Shun He; Jianhong Chu; Sumithira Vasu; Youcai Deng; Shunzong Yuan; Jianying Zhang; Zhijin Fan; Craig C Hofmeister; Xiaoming He; Henry C Marsh; Steven M Devine; Jianhua Yu
Journal:  Biol Blood Marrow Transplant       Date:  2013-12-21       Impact factor: 5.742

10.  TAK1 inhibition ameliorates survival from graft-versus-host disease in an allogeneic murine marrow transplantation model.

Authors:  Ayako Kobayashi; Shinichi Kobayashi; Kosuke Miyai; Yukiko Osawa; Toshikatsu Horiuchi; Shoichiro Kato; Takaaki Maekawa; Takeshi Yamamura; Junichi Watanabe; Ken Sato; Hitoshi Tsuda; Fumihiko Kimura
Journal:  Int J Hematol       Date:  2017-10-12       Impact factor: 2.490

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.